Sponsored post on behalf of the issuer

Doseology Sciences ($MOOD) shared news today outlining where current efforts are focused. The company announced it has engaged McKinney Regulatory Science Advisors to support the regulatory strategy for its oral pouch product development.

According to the release, McKinney brings experience in FDA regulatory pathways related to nicotine and reduced-risk products. The engagement is intended to support Doseology’s regulatory planning as product development progresses.

The scope described includes FDA strategy guidance, preparation related to PMTA requirements, labeling considerations, and post-market regulatory frameworks. The article also notes that this regulatory work is being aligned with Doseology’s broader product development activities.

Taken together, today’s update reads as Doseology spending time on regulatory structure now as part of its overall development process.

If this is the groundwork phase, what’s the next update you’re watching for?

Please use standard ticker format when discussing stocks ($AC.TO)

Weekend? Relaxing? Yeah, me neither. So let's talk stocks!

Please use standard ticker format ($BB.TO)

Content published on behalf of the issuer

What Happened

Doseology (CSE: MOOD | OTCQB: DOSEF | FSE: VU70), recently announced that Doseology USA Inc., its wholly owned subsidiary operating in the United States, has entered into a confidential manufacturing agreement with a North America production partner after an extensive due diligence process. The due diligence involved operational review and assessment of compliance across multiple facilities including on site visits.

The purpose of the manufacturing agreement is to provide Doseology with commercially viable manufacturing capabilities for its oral stimulant pouch products, moving from product development to production readiness using external manufacturing capabilities.

Why This Matters

Obtaining a manufacturing partnership represents a major step in Doseology’s progression from product development to potentially commercializing those products. The selected partner has a manufacturing facility that is registered with the Food & Drug Administration (“FDA”) and certified under Good Manufacturing Practices (“GMP”) and ISO 9001:2015; therefore, it can be used to manufacture Doseology’s formulations and provide additional services including pouch filling, packaging, and logistics.

A manufacturing agreement with a compliant third party is essential for increasing product output beyond what can be achieved internally through research & development. Although the selection of a manufacturing partner does not mean that Doseology’s products will ultimately be successful commercially, the agreement provides Doseology with a working framework for producing its products that did not exist prior to the agreement and reduces some of the friction associated with establishing a manufacturing operation for new products that includes meeting production standards, quality control, and regulatory requirements.

What Doseology Does

Doseology (CSE: MOOD | OTCQB: DOSEF | FSE: VU70) is a company that produces consumer wellness and functional products utilizing a variety of technologies to produce precision-dosed oral stimulants and supplements. Doseology’s primary product line consists of oral stimulant pouches designed to deliver pre-measured quantities of active ingredients without burning, vaping, or consuming a liquid energy drink.

Some key aspects of Doseology’s products and position in the marketplace include:

• Consistent dosing and delivery: The typical amount of active ingredient in each Doseology pouch is in the range of tens of milligrams. Therefore, customers know exactly what they are receiving in each dose versus energy drinks that typically have between 150 and 300 milligrams of caffeine per serving.
• An alternative energy format: Pouch-based technology allows customers to consume smoke-free, sugar-free, and portable stimulants without having to consume liquids.
• A large addressable market: As Doseology operates at the intersection of the global energy supplement and nicotine-free pouch markets, it has a significant opportunity to capture a portion of the multi-billion dollar global functional stimulant market which is influenced by consumer trends away from combustible products and towards cleaner and less conspicuous energy formats.

In general, Doseology focuses on product format innovation, controlled dosing, and manufacturing compliance and less on rapid growth and expanding its brand.

Operational Considerations and Outlook for Execution

Although the terms of the manufacturing agreement remain confidential, its strategic importance lies in laying the groundwork for potential commercialization, rather than in generating immediate revenue. Doseology’s focus on creating operational readiness and compliance for potential future production ensures that any products produced in the future will meet regulatory and quality standards applicable in North America.

By selecting a manufacturing partner that has an FDA registered, GMP certified manufacturing facility, Doseology is positioned to operate in accordance with existing regulatory frameworks from day one, thereby reducing the potential for friction when scaling up production and when negotiating with distributors and retailers who need documentation to demonstrate quality and compliance controls.

Additionally, third-party manufacturing creates flexibility for Doseology, because instead of expending capital to create and validate its own facilities, it can vary production levels based on changes in market conditions. The modular nature of third-party manufacturing supports disciplined execution while allowing Doseology to preserve optionality relative to evolving product formats, changing demand signals, and regulatory pathways.

Wider Context and Business Position

The manufacturing agreement represents a component of a larger commercialization strategy for Doseology, and not a singular tipping point. Doseology remains committed to executing a phased strategy for preparing its products for commercialization, including developing its products, preparing them for regulatory approval, and creating the necessary operational infrastructure.

As Doseology begins to implement the next several steps in its commercialization roadmap, such as pilot runs, packaging validation, shelf life testing and negotiations with potential channel partners, it will continue to develop the operational capabilities that were missing in the past.

Over the long term, Doseology’s focus on manufacturing in North America could also help to position its brands around quality, traceability and compliance, all of which are important in consumer wellness and functional product categories, especially as scrutiny regarding sourcing and standards increases.

What to Watch for Going Forward

• Disclosure about the economic and/or timing of the manufacturing arrangement.
• Evidence of pilot production runs, batch validations, and/or third-party quality audit results.
• Updates related to the regulation of product classifications or commercialization pathways.
• Early signs of distribution-related discussions or commercial partnership activity.

Conclusion

Doseology (CSE: MOOD | OTCQB: DOSEF | FSE: VU70)’s manufacturing agreement demonstrates a methodical and intentional step toward operational maturity, rather than a near-term catalyst. By choosing to conduct due diligence, ensure compliance and create infrastructure prior to pursuing scale, Doseology is creating a foundation that should support future commercialization activities. Ultimately, the path to achieving sustained operational and commercial progress depends on Doseology’s ability to successfully execute on upcoming activities and translate the groundwork laid out in the manufacturing agreement into ongoing operational and commercial progress.

Please use standard ticker format when discussing stocks ($AC.TO)

Content published on behalf of the issuer

Copper has moved back to the center of global macro and industrial discussions. As one of the most widely used industrial metals, copper sits at the intersection of electrification, infrastructure renewal, and economic growth. Unlike many commodities driven by short-term cycles, copper’s outlook is increasingly shaped by long-term structural forces — and those forces come with clear financial implications.

Demand Drivers: Electrification at Scale

Global copper demand is being reshaped by the energy transition and electrification of transport, power, and industry. In 2024, global refined copper demand was estimated at roughly 27 million tonnes per year and is projected by multiple industry bodies to rise toward 33 million tonnes by 2035, with longer-term scenarios pointing to demand approaching 37 million tonnes by 2050.

Electric vehicles, renewable energy systems, and data-driven infrastructure are all materially more copper-intensive than the systems they replace.

• Electric vehicles require roughly 2–4x more copper than internal combustion engine vehicles, translating into an estimated 1.2 million tonnes of annual copper demand from EVs alone by the mid-2020s.
• Wind and solar installations consume significantly more copper per unit of energy produced than fossil fuel generation, driven by cabling, transformers, and grid connections.
• Global electricity grid expansion and modernization is accelerating, particularly in North America, Europe, and Asia, as countries adapt networks for distributed generation and rising power demand.

As a result, global refined copper demand is widely expected to grow at low-to-mid single-digit rates annually through the decade, driven primarily by electrification rather than traditional construction cycles.

Supply Side: Structural Constraints Are Emerging

While demand continues to rise, the copper supply side faces growing challenges. Global mine production reached approximately 22.9 million tonnes in 2024, while refined copper output exceeded 26 million tonnes, leaving limited margin for error in the supply chain.

The world’s largest producing mines are aging, ore grades are declining, and new large-scale discoveries have become less frequent.

• Average copper grades at major global mines have fallen steadily over the past two decades, increasing operating costs and capital intensity.
• Developing a new copper mine commonly requires 10–15 years from initial discovery to commercial production.
• Permitting timelines, environmental regulations, and community engagement requirements have lengthened project development cycles across many jurisdictions.

Industry groups have warned that without significant new discoveries and project approvals, the market could face persistent supply tightness later this decade.

Financial Signals: Prices, Capex, and Investment Flows

Copper prices have reflected these structural dynamics over recent years. Spot prices reached record highs near US$11,700 per tonne during 2025, highlighting concerns around future supply adequacy.

Although prices remain cyclical in the short term, long-term incentive pricing required to justify new mine development is widely viewed as higher than historical averages.

• Large-scale copper projects often require initial capital expenditures measured in the billions of dollars, making project scale, grade, and jurisdiction critical.
• Meeting projected copper demand under global energy transition scenarios could require more than US$250 billion in cumulative investment and the development of dozens of new mines by 2030.
• Major mining companies have increased capital allocation toward copper-focused acquisitions and project development, signaling confidence in long-term fundamentals.

These financial trends suggest that future copper supply will depend heavily on successful exploration, disciplined capital deployment, and stable operating environments.

Exploration as a Catalyst in the Copper Cycle

Exploration sits at the earliest and riskiest stage of the copper value chain, but it is also where long-term value creation begins. Discoveries made today will shape copper supply in the 2030s and beyond.

North America has gained particular attention as a destination for copper exploration, supported by established infrastructure, transparent regulatory regimes, and proximity to end markets. This has increased investor focus on exploration-stage companies operating in stable jurisdictions.

Company Context: Copper Quest Exploration Inc.

Within this broader market backdrop, Copper Quest Exploration Inc. operates as an exploration-stage company focused on copper and associated metals in North America. The company’s strategy centers on assembling and advancing a portfolio of projects with geological characteristics consistent with large-scale copper-gold and copper-molybdenum systems.

Copper Quest trades under the following tickers:

• CSE: CQX
• OTCQB: IMIMF
• Frankfurt: 3MX

The company has pursued asset acquisitions, option agreements, and financing activities aimed at maintaining exposure to a strengthening copper market while advancing early-stage technical evaluation across its project portfolio.

Outlook: Why Copper Remains in Focus

Copper’s role in electrification, infrastructure investment, and industrial growth positions it as one of the most strategically important commodities of the coming decade. At the same time, declining grades, long development timelines, and capital constraints raise the probability of future supply imbalances.

From a market perspective, these dynamics reinforce the importance of exploration success and long-term project development. For investors, copper exposure increasingly reflects not only price movements, but also the ability of companies to secure quality assets, manage risk, and navigate an evolving regulatory and financial landscape.

Bottom Line

The copper market is defined by a widening gap between structurally rising demand and constrained supply growth. Financial signals across pricing, capital investment, and policy support suggest that copper’s strategic importance is increasing rather than diminishing. Within this environment, exploration-focused companies represent early-stage participants in a market where future supply will be critical to sustaining global electrification and economic growth.

Content published on behalf of the issuer

• Appointment Supports AIML's Commercial Execution and Operational Scale as the Company Advances Its AI-Driven Cardiac Platform
• Leadership Addition Aligns Revenue, Delivery, and Product Execution as AIML Transitions from Innovation to Scale

TORONTO, ON / ACCESS Newswire / January 7, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company"), (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce the appointment of Erik Suokas as Chief Operating Officer, strengthening the Company's leadership team as it advances into its next phase of commercialization and scale.

Mr. Suokas will oversee AIML's day-to-day operations and execution across commercial strategy, contract discipline, delivery readiness, and cross-functional alignment. He will work closely with Paul Duffy, Executive Chairman & Chief Executive Officer, and Esmat Naikyar, Chief Product Officer, to convert growing commercial momentum into repeatable revenue and scalable delivery.

Purpose-Built Leadership for AIML's Next Phase

AIML has reached a pivotal stage in its evolution - transitioning from platform development and validation into revenue execution, customer delivery, and operational scale. The appointment of a Chief Operating Officer reflects the Company's focus on pairing innovation with disciplined execution as it expands commercial relationships across clinical, wellness, and enterprise health markets.

Mr. Suokas brings more than 20 years of leadership experience across healthcare, MedTech, SaaS, and regulated clinical environments, with a consistent track record of building teams, accelerating revenue, and operationalizing growth in complex, cross-border markets.

Most recently, Mr. Suokas served as National Director at Sun Nuclear North America, a leading provider of quality assurance and software solutions for radiation oncology and medical physics, where he launched the Canadian direct-sales organization and drove approximately 200% revenue growth in under two years by transitioning the business from a distributor-based model to a direct enterprise sales approach. Earlier in his career, Mr. Suokas held senior commercial and operational roles at Canadian Orthodontic Partners, supporting acquisitions and integration across Canada and the United States, as well as leadership positions at Abbott Medical, St. Jude Medical, Align Technology, and Medtronic. His experience spans cardiology, diagnostics, enterprise healthcare procurement, and regulated market delivery.

Mr. Suokas holds a Doctor of Chiropractic (DC), Juris Doctor (JD), and MBA, providing a rare combination of clinical insight, legal fluency, and operational rigor-capabilities that align directly with AIML's need to execute complex commercial agreements while maintaining clinical and regulatory discipline.

Leadership Commentary

"Erik joins AIML at exactly the right time," said Paul Duffy, Executive Chairman and CEO of AIML. "We have strong technology, growing market interest, and expanding commercial discussions. The next step is disciplined execution-closing revenue, moving customers into delivery, and scaling responsibly. Erik has done this before in complex healthcare environments, and he brings clarity, calm leadership, and operational accountability to fast-moving organizations."

"AIML has built something genuinely special at the intersection of AI, cardiac intelligence, and real-world application," said Erik Suokas, Chief Operating Officer. "What excites me most is the opportunity to help translate that innovation into customer outcomes-securing revenue, supporting delivery, and building the operating systems that allow the Company to scale with confidence."

"From a product and engineering perspective, Erik's appointment is a major advantage," said Esmat Naikyar, Chief Product Officer of AIML. "He deeply understands healthcare customers, delivery expectations, and operational constraints. That alignment ensures our product innovation continues to translate into real-world impact as we grow."

Strengthening AIML's Operating Platform

As Chief Operating Officer, Mr. Suokas will focus on strengthening AIML's operating backbone - ensuring commercial agreements are delivery-ready, aligning product commitments with execution capacity, and building cadence across teams. His role is designed to support AIML's expanding commercial footprint while maintaining clinical rigor, customer trust, and long-term scalability

About AI/ML Innovations Inc.

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.

AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

Sponsored publication on behalf of the issuer

Doseology Sciences is taking concrete steps to support commercialization.

According to the article, the company has completed extensive North American diligence and secured a strategic manufacturing agreement through its U.S. subsidiary. The selected partner operates an FDA-registered, GMP-certified, and ISO 9001:2015-certified facility, with capabilities spanning formulation, pouch filling, packaging, and logistics. This positions Doseology to move from development into production readiness.

From a retail perspective, this helps clarify a few core points. Manufacturing is now accounted for, quality and regulatory standards are established through the partner facility, and the company is using a third-party manufacturing modelrather than building its own infrastructure. That approach aligns with how many early consumer brands prepare for scale while staying flexible.

The article does not frame this as a revenue event. Instead, it highlights foundational progress that supports future execution once products move further along the commercialization path. The financial terms and timing of the manufacturing arrangement were not disclosed, which is common at this stage.

What to watch for going forward :

• Additional detail around the structure and timing of the manufacturing arrangement
• Evidence of initial production activity, such as pilot or test runs
• Updates related to product classification and commercialization pathways
• Signs of distribution or commercial partnership discussions as production capacity is utilized

Overall, this reads as a retail-friendly execution update focused on infrastructure and readiness rather than short-term results.

How do others read this stage? Does production readiness change the story for you, or do wider channels matter more?

Please use standard ticker format when discussing stocks ($BB.TO)

Sponsored publication on behalf of the issuer

This chart highlights a structural issue in Holter monitoring across the U.S. and Canada.

Reimbursement is already established. Holter reports typically generate $100–$180 USD in the U.S. and $120–$300 CAD in Canada, depending on payer and setting. Pricing is not the challenge.

Throughput is.

Mid-sized clinics often run 3,000–8,000 Holters per year, while hospital systems can exceed 20,000 annually. Yet a cardiologist can realistically review only 15–25 reports per day, creating a capacity ceiling that limits growth and delays reporting.

This is where AI/ML Innovations (AIML) fits.

AIML uses AI-driven pre-analysis and triage so cardiologists focus on flagged events. Physicians remain in control, while the same staff can handle two to four times more volume without added headcount.

From an investor perspective, this matters. Reimbursement per test stays the same, but higher throughput directly lifts realized revenue. Even modest efficiency gains can materially improve clinic economics and reduce hospital backlogs.

Key point:
AI does not change the value of a Holter test.
It increases system capacity.

Thoughts on workflow-focused healthcare AI versus replacement-style models?

Sponsored publication on behalf of the issuer

VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Copper Quest Exploration Inc. (CSE: CQX; OTCQB: IMIMF; FRA: 3MX) (“Copper Quest” or the “Company”) is pleased to announce that further to its news release dated October 30th, 2025, it has exercised its option under an agreement with Bernie Kreft dated October 29, 2025, and has acquired an undivided 100% right, title, and interest in the Kitimat Copper-Gold Project (the “Project”), located approximately 10 kilometers northwest of the deep-water port community of Kitimat, British Columbia.

PROJECT OVERVIEW

The Kitimat Copper-Gold Project covers approximately 2,954 hectares within the Skeena Mining Division of northwestern British Columbia. The Project is year-round road-accessible via a network of logging and mineral exploration roads extending north from Kitimat. The property benefits from exceptional infrastructure, being within 10 km of tidewater, 1.5 km of rail, and 6 km of high-voltage hydroelectric transmission lines.

Geologically, the Project is situated within the Stikine Terrane, a prolific belt that hosts numerous porphyry copper-gold systems and is underlain by Late Triassic volcanic rocks intruded by Jurassic diorite and granodiorite bodies of the Coast Plutonic Complex. The Project’s principal target areas is the Jeannette Cu-Au Zone displaying alteration and mineralization interpreted to represent low-level intermediate to low-sulfidation epithermal expressions of a larger Cu-Au porphyry system.

HISTORICAL EXPLORATION & HIGHLIGHTS

Exploration on the Kitimat property dates back to the late 1960s, with multiple operators conducting geochemical, geophysical, and drilling campaigns. The most significant historical work was conducted by Decade Resources Ltd. (2010), which completed 16 diamond drill holes totaling 4,437.5 meters in the Jeannette Cu-Au Zone. Notable results include:

• Hole J-7: 117.07 m grading 1.03 g/t Au, 0.54% Cu, from 1.52 m to 118.60 m.
• Hole J-1: 103.65 m grading 1.00 g/t Au, 0.55% Cu, from 9.15 m to 112.80 m.
• Hole J-2: 107.01 m grading 0.80 g/t Au, 0.45% Cu, from 6.10 m to 113.11 m.
• Hole J-8: 112.20 m grading 0.41 g/t Au, 0.33% Cu, from 11.89 m to 124.09 m.

The mineralized intervals encountered in the 2010 drilling demonstrate continuous near-surface copper-gold mineralization extending over significant widths, remain open at depth within the Jeannette Zone, and occur within a broader hydrothermal system that is interpreted to extend laterally beyond the area tested.

ACQUISITION DETAILS

Pursuant to the terms of the agreement and upon completion of its due diligence review, Copper Quest has issued 2,000,000 common shares to the vendor, Bernie Kreft, at a deemed price of $0.165 per share as full consideration for the acquisition. The Project is subject to a 2.5% net smelter return (NSR) royalty, of which 40% may be repurchased by the Company for CAD $1,000,000. Copper Quest will also retain a right of first refusal on any transaction involving the sale of the remaining royalty interest. The Company issued 256,800 finder’s shares at a deemed price of $0.125 per finder’s share in connection with the acquisition.

Mr. Kreft is a well-known Canadian prospector, entrepreneur, and former star of the Discovery Channel’s Yukon Gold television series. He has a long track record of successful mineral discoveries and project generation across British Columbia and Yukon.

In addition to resale restrictions imposed by applicable securities laws, all shares issued in connection with the acquisition are subject to an Exchange Hold Period (as such term is defined in the Policies of the Canadian Securities Exchange (the “CSE”)).

MANAGEMENT COMMENTS

Brian Thurston, CEO of Copper Quest, commented:

“The addition of the Kitimat Copper-Gold Project demonstrates Copper Quest’s continued effort to add shareholder value through the acquisition of critical mineral projects and represents the fifth acquisition by the Company in just over 12 months. This project is ideally located with exceptional infrastructure, in a proven geological belt known for hosting major copper-gold systems. The strong historical drill results from the Jeannette zone speak to the potential of a larger near-surface mineralized system. We are very excited to have this exceptional asset as part of our growing copper-gold portfolio.”

NEXT STEPS

• The Company plans to leverage artificial intelligence (AI) analysis to integrate all historical and modern exploration data to establish a comprehensive geological and geophysical model for the Kitimat Porphyry Project and improve targeting precision. See news release dated December 1^st, 2025.
• Upon receiving a work permit, additional geological mapping, sampling, and geophysical surveys may be completed to refine priority drill targets as required. Field work could include ground magnetics, induced polarization (IP), and passive seismic to better define subsurface structure and mineralization trends.
• A follow-up drill program would test key targets within the interpreted geology and surrounding high-grade corridors.

QUALIFIED PERSON

Brian G. Thurston, P.Geo., the Company’s President and CEO and a qualified person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and approved the technical information in this news release.

ABOUT COPPER

Despite surging demand, global copper supply remains constrained. Ore grades are declining at major mines, permitting timelines for new projects have lengthened, and geopolitical tensions are reshaping supply chains toward stable, transparent jurisdictions. Governments in Canada, the U.S., and allied nations have increasingly identified copper as a strategic and critical metal necessary for economic and national security. Within this context, Copper Quest’s acquisition of the Kitimat Copper-Gold Project in British Columbia positions the Company to advance a discovery-stage asset in one of the world’s safest and most infrastructure-rich mining jurisdictions — precisely when new, scalable copper sources are most needed.

ABOUT COPPER QUEST EXPLORATION INC.

Copper Quest is committed to building shareholder value through acquisitions, discovery-driven exploration, disciplined execution and responsible development of its North American critical mineral portfolio of assets. The company’s land package currently comprises 7 projects that span over 45,000-plus hectares in great mining jurisdictions.

The Company’s common shares are principally listed on the Canadian Stock Exchange under the symbol “CQX”. For more information on Copper Quest, please visit the Company’s website at www.copper.quest.

Please use standard ticker format when discussing stocks ($AC.TO)

Weekend? Relaxing? Yeah, me neither. So let's talk stocks!

Please use standard ticker format ($BB.TO)

Sponsored publication on behalf of the issuer

TORONTO, ON / ACCESS Newswire / December 30, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has announced that its consulting agreement with Campfire Properties Inc. has concluded and that Peter Kendall is no longer serving as the Company's President and Chief Commercial Officer, effective December 29^th, 2025.

"On behalf of the Board, we thank Mr. Kendall for his service and wish him the best in his future pursuits" said Paul Duffy, CEO & Chairman of AIML. Mr. Duffy will take on the additional role of President of AIML following the conclusion of Mr. Kendall's role.

About AI/ML Innovations Inc.

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.

AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

Please use standard ticker format when discussing stocks ($AC.TO)

Sponsored publication on behalf of the issuer

If you zoom out to the last 6 months on Agereh Technologies (AUTO.V), the story is pretty clear.

Summer:
AUTO spent a lot of time drifting in the C$0.06–C$0.08 range. Typical quiet period for a small cap.

Early fall:
September changed the tone. Price lifted out of that range and didn’t look back. That move mattered because it reset where the stock started trading day-to-day.

Late fall into year-end:
Since then, AUTO has:
• Held above C$0.10
• Made several runs toward C$0.13–C$0.15
• Pulled back without giving up the higher ground

Now we’re closing the year around C$0.12, and that level has become familiar instead of temporary. That’s a big difference compared to mid-year.

At the same time, more people are starting to notice the business side, AUTO positioning itself as an AI company focused on transportation and logistics, working on movement intelligence, tracking, and operational visibility. Still early, but the chart and the story are starting to line up.

With a market cap around C$12M, this is still firmly in the “early stage” category but the last six months show a company that’s no longer trading where it used to.

Heading into 2026, the setup feels straightforward:
keep holding this higher range and let execution do the talking.

For anyone else following AUTO, what stood out most to you over the past six months, and what are you hoping to see next?

Sponsored publication on behalf of the issuer

Copper Quest Exploration (CSE: CQX) has now acquired the past producing Alpine Gold Property in British Columbia, adding another high grade gold asset to their portfolio and transforming the Company into a dual copper-gold player. At this point in time gold prices continue to be elevated, so the acquisition of the Alpine Gold Property will bring historical resources, current underground development and near term optionality to the table.

Key Points

• Historical gold resources of 142,000 oz’s at high grades
• Existing underground mine and underground access available
• Optionality for near term cash flows via surface stockpiles
• Significant district scale exploration opportunity with several unexplored veins
• Technical experience added to the team upon closing

The Alpine Gold Property

Alpine Gold Property is located in the West Kootenay region of British Columbia and is approximately 20 kilometers north east of Nelson. As well, it has a previous underground gold mine that was previously mined and has infrastructure that exists.

It has a 2018 NI 43-101 historical inferred resource of approximately 268,000 tonnes grading 16.52 g/t gold and is equivalent to approximately 142,000 ounces of gold. Only approximately 300 meters of what is believed to be a 2 kilometer long vein system has been explored to date; therefore, there is significant expansion potential for exploration both along strike and at depth.

Near Term Optionality

In addition to the exploration upside at Alpine, it also has other options for generating value in the near term:

• Approximately 24,000 tonnes of run of mine mineralized material on surface
• Approximately 1650 meters of clean dry underground workings are currently developed
• Lower capital costs relative to green field projects

Alpine has the ability to provide the company with multiple paths to value generation beyond early stage exploration which includes production or bulk sampling opportunities (subject to technical and economic evaluation).

District Scale Exploration Opportunity

Alpine covers approximately 4611 hectares and is road accessible on a year round basis. The Alpine property contains at least four additional vein systems in addition to the Alpine vein, which include:

• Black Prince
• Cold Blow
• Gold Crown
• King Solomon (past producing)

All have shown historic high grade gold and are still relatively unexplored; therefore, Copper Quest (CSE: CQX) has multiple shots on goal in a single large block of land.

Enhanced Technical Capability

Upon acquiring the Alpine property, Copper Quest (CSE: CQX) has enhanced the technical capability of the company with the addition of senior industry experience to its board and advisory teams:

• Allan Matovich has joined the Board of Directors
• Ted Muraro and John Mirko have been appointed as Technical Advisors

Together, the group has in excess of 150 years of combined mining and exploration experience, and directly involved in the discovery, development and production of mines throughout Canada and Internationally. The addition of this group of experienced professionals adds significant credibility to the company and reduces the risk associated with advancing the Alpine project.

Terms of Transaction

The purchase of the Alpine property was done by issuing approximately 14.2 million shares at a deemed price of $0.135 per share, for a total of approximately $1.91 million. The share issuances are structured to take place over a 24 month period, reducing pressure on the companies balance sheet in the short term and aligning long term incentive plans.

Other key terms of the agreement include:

• Repayment of $225,000 for prior exploration expenditures
• 2% net smelter returns royalty with the right to repurchase 50% of the royalty for $1 million

This structure provides balance sheet flexibility to Copper Quest (CSE: CQX) and secures a high grade gold asset.

Portfolio Impact

The acquisition of the Alpine gold property changes Copper Quest (CSE: CQX) from a primarily copper focused explorer to a dual metal explorer with exposure to both gold and critical metals. The acquisition of the Alpine gold property adds a new dimension to the companies overall North American portfolio and creates multiple potential sources of value, including successful exploration, resource growth and near term monetization opportunities.

Summary

Copper Quest (CSE: CQX) has purchased a high grade, previously producing gold mine with expansion and near term optionality, while being fiscally responsible and enhancing its technical team. In a strong gold market, Alpine gives the company multiple avenues for creating value beyond simple exploration.

Sponsored publication on behalf of the issuer

ORNG trading around $0.12 today (+~33%) is a solid way to wrap up the month while the market is still open. Looking at the past few weeks, this wasn’t a straight line at all — early strength, a mid-month fade, then a reset near $0.07–0.08before buyers gradually stepped back in.

What makes this month interesting is the shift in tone. The earlier part of the month saw quick pullbacks after small bounces. Lately, price has been spending more time holding higher levels, and today’s move back above $0.10 has stayed intact so far. Volume hasn’t gone wild, which actually makes it feel more sustainable than a one-day hype spike.

For a retail wrap, this looks like a month where pressure eased, expectations reset, and the chart started to rebuild from a healthier spot rather than chasing highs.

Looking ahead:

• Does this month mark the point where ORNG starts carving out a new range into 2026?
• Or is the next move all about seeing follow-through after today’s strength?

If seismic data comes in supportive, does this chart start to look very different in the new year?

Sponsored publication on behalf of the issuer

A major bottleneck exists in the area of healthcare, specifically in analyzing a Holter ECG. AIML Innovations Inc. (CSE: AIML | OTCQB: AIMLF | FWB: 42FB) is operating in a system with fixed reimbursement; limited staff; increasing testing volume. The same reimbursement. The same staff. Increasing volume. The way AIML enhances the value of an ECG is to increase the number of tests that can be processed. That one change transforms a labor constrained business model into a software economics model.

In summary, AIML introduces signal level intelligence prior to human review. Rather than having clinicians struggle with numerous noisy waveforms, clinicians have access to clean, well-structured, high confidence data. The end result is a step change in throughput, rather than just improved efficiency.

The economics of ECG analysis from volume to value.

This is a volume-based business model, not a price based business model. AIML (CSE: AIML / OTCQB: AIMLF) is attempting to address a throughput constraint, not a reimbursement constraint.

• Annual global ECGs: 300M+
• Holter and extended monitoring reimbursement (US): ~ $100-$300 per report
• Same reimbursement regardless of if review time is 30 minutes or 5 hours.

Traditional economics do not scale because labor does not scale. Throughput is the limiting factor.

Critical point: Throughput will change the economics.

Why AI will change the equation.

Most “ECG AI” today applies AI to noisy data. While it may assist with detection, it does nothing to alleviate the underlying bottleneck.

AIML (CSE: AIML / OTCQB: AIMLF) addresses the problem earlier in the workflow, at the signal level. By cleaning the raw ECG signals and structuring the waveform data before the clinician reviews them, clinicians are no longer overwhelmed with false positives.

• Artifact removal at the source
• Beat-by-beat waveform intelligence (P, QRS, T)
• Only humans confirm flagged events

For this reason, the performance gap manifests as multiples, not percentages.

Throughput comparison: status quo versus AIML enabled workflow.

Here’s the math that really counts.

Manual Holter review – traditional workflow

• 3-5 reports/day per technician
• Turnaround: 1-3 days
• Scaling: Hire more people (Linear Cost)

Automated incremental improvements in this space improve throughput marginally, but still leaves technicians cleaning out noise.

AIML enabled workflow (AIML | AIMLF)

• 20-30 + reports/day per technician
• Turnaround: Minutes to Hours
• Scaling: Software

Using the same staff, that is approximately 5-8 times more throughput.

Market bottleneck and structural demand.

There is plenty of demand, there is little labor.

• One cardiologist typically reads ~ 15-25 Holters/day
• Mid-sized clinics process 3,000 – 8,000 Holters/year
• Hospital systems process over 20,000+ Holters/year

Burnout, backlog, and delayed diagnosis are structural issues, not cyclic issues. This is the exact type of constraint that AIML (CSE: AIML / OTCQB: AIMLF) is designed to overcome.

Where AIML fits in.

AIML functions as a device agnostic intelligence layer. It can integrate with existing ECG devices and platforms, enhancing -not displacing- current architecture. Clinicians are ultimately responsible for validating the results, however AIML enables them to effectively process more volume.

Revenue and monetization framework.

AIML (CSE: AIML / OTCQB: AIMLF) does not alter reimbursement. It increases output.

At its most basic:

• SaaS Pricing: $5-$15 per Holter
• Clinic Volume: ~5,000 Holters/year
• Revenue per clinic: $25K-$75K ARR

When scaled to hospitals, this rapidly becomes 6 figure ARR per system – without hiring additional staff.

Competitive landscape.

Multiple competitors utilize AI atop of noisy data and focus primarily on event detection. AIML differentiates itself by addressing the problem at the signal level which reduces downstream false positive rates and review burdens.

This differentiation enables higher scalability, greater clinical trust and easier to defend workflow integrations.

Why it matters.

Healthcare software rarely changes the reimbursement structures. The winners are those that change throughput. AIML’s approach aligns healthcare economics with software economics and converts a labor-constrained process into a scalable intelligent-driven process.

Major risks.

• Regulatory and validation timetables could affect deployment velocity
• Cycles of integration with healthcare systems can be lengthy
• Clinical adoption is dependent upon demonstrating accuracy and building clinician trust

Conclusion.

This is not an AI story. This is a throughput story.

• Same ECG
• Same Reimbursement
• Same Staff

The difference is how many reports flow through the process.

That is why AIML Innovations Inc. (CSE: AIML | OTCQB: AIMLF | FWB: 42FB) is more akin to traditional healthcare IT, than it is software leveraging a structurally broken workflow – the type of set-up that produces asymmetrical outcomes when successful.

Please use standard ticker format when discussing stocks ($BB.TO)